CeNeRx raises $4.85M for TriRima trial, CNS agents

12/15/2011 | Pharmaceutical Business Review Online

CeNeRx BioPharma has secured $4.85 million in funding from investors including L Capital Partners and Omega Funds. The company will use the money to finish its second-phase trial of TriRima, its new antidepressant formulation, and to advance agents for disorders of the central nervous system.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ